Chymotrypsin attenuates adjuvant-induced arthritis by downregulating TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6 expression in Sprague–Dawley rats

References

• Smolen J, Aletaha D, McInnes I. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Burmester G, Pope J. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–2348.
   PubMed Web of Science ®Google Scholar
• Ru J, Ma J, Niu H, et al. Burden and depression in caregivers of patients with rheumatoid arthritis in China. Int J Rheum Dis. 2019;22(4):608–613.
   PubMed Web of Science ®Google Scholar
• Tchetverikov I, Lohmander LS, Verzijl N, et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis. 2005;64(5):694–698.
   PubMed Web of Science ®Google Scholar
• Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9–17.
   PubMed Web of Science ®Google Scholar
• Ben Mrid R, Bouchmaa N, Ainani H, et al. Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother. 2022;151:113126.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Perspectives from masters in rheumatology and autoimmunity: can we get closer to a cure for rheumatoid arthritis? Arthritis Rheumatol. 2015;67(9):2283–2291.
   PubMed Web of Science ®Google Scholar
• Viswanatha Swamy A, Patil P. Effect of some clinically used proteolytic enzymes on inflammation in rats. Indian J Pharm Sci. 2008;70(1):114–117.
   PubMed Web of Science ®Google Scholar
• Jutila M, Kishimoto T, Finken M. Low-dose chymotrypsin treatment inhibits neutrophil migration into sites of inflammation in vivo: effects on Mac-1 and MEL-14 adhesion protein expression and function. Cell Immunol. 1991;132(1):201–214.
   PubMed Web of Science ®Google Scholar
• Ghaffarinia A, Jalili C, Riazi-Rad F, et al. Anti-inflammatory effect of chymotrypsin to autoimmune response against CNS is dose-dependent. Cell Immunol. 2014;292(1–2):102–108.
   PubMed Web of Science ®Google Scholar
• RaviKumar T, Ramakrishnan M, Jayaraman V, et al. Effect of trypsin-chymotrypsin (Chymoral Forte D.S.) preparation on the modulation of cytokine levels in burn patients. Burns: J Int Soc Burn Inj. 2001;27(7):709–716.
   PubMed Web of Science ®Google Scholar
• Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529–543.
   PubMed Web of Science ®Google Scholar
• Leipner J, Iten F, Saller R. Therapy with proteolytic enzymes in rheumatic disorders. BioDrugs: Clin Immunother Biopharm Gene Ther. 2001;15(12):779–789.
   Google Scholar
• Uttra AM, Shahzad M, Shabbir A, et al. Ephedra gerardiana aqueous ethanolic extract and fractions attenuate Freund complete adjuvant induced arthritis in Sprague Dawley rats by downregulating PGE2, COX2, IL-1β, IL-6, TNF-α, NF-kB and upregulating IL-4 and IL-10. J Ethnopharmacol. 2018;224:482–496.
   PubMed Web of Science ®Google Scholar
• Chintalacharuvu SR, Urankar-Nagy N, Petersilge CA, et al. Treatment of collagen induced arthritis by proteolytic enzymes: immunomodulatory and disease modifying effects. J Rheumatol. 2001;28(9):2049–2059.
   PubMed Web of Science ®Google Scholar
• Rovenská E, Svík K, Stancíková M, et al. Inhibitory effect of enzyme therapy and combination therapy with cyclosporin a on collagen-induced arthritis. Clin Exp Rheumatol. 2001;19(3):303–309.
   PubMed Web of Science ®Google Scholar
• Choudhary N, Bhatt L, Prabhavalkar K. Experimental animal models for rheumatoid arthritis. Immunopharmacol Immunotoxicol. 2018;40(3):193–200.
   PubMed Web of Science ®Google Scholar
• Sprangers S, Everts V. Molecular pathways of cell-mediated degradation of fibrillar collagen. Matrix Biol. 2019;75–76:190–200.
   PubMed Web of Science ®Google Scholar
• Wang X, Tang K, Wang Y, et al. Elevated microRNA‑145‑5p increases matrix metalloproteinase‑9 by activating the nuclear factor‑κB pathway in rheumatoid arthritis. Mol Med Rep. 2019;20(3):2703–2711.
   PubMed Web of Science ®Google Scholar
• Dancevic CM, McCulloch DR. Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis. Arthritis Res Ther. 2014;16(5):429.
   PubMed Web of Science ®Google Scholar
• Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. IJMS. 2017;18(5):905.
   Google Scholar
• Malemud CJ. Matrix metalloproteinases and synovial joint pathology. Prog Mol Biol Transl Sci. 2017;148:305–325.
   PubMed Web of Science ®Google Scholar
• Konttinen Y, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999;58(11):691–697.
   PubMed Web of Science ®Google Scholar
• Barchowsky A, Frleta D, Vincenti M. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine. 2000;12(10):1469–1479.
   PubMed Web of Science ®Google Scholar
• Rigoglou S, Papavassiliou AG. The NF-κB signalling pathway in osteoarthritis. Int J Biochem Cell Biol. 2013;45(11):2580–2584.
   PubMed Web of Science ®Google Scholar
• Aravilli RK, Vikram SL, Kohila V. Phytochemicals as potential antidotes for targeting NF-κB in rheumatoid arthritis. 3 Biotech. 2017;7(4):253.
   PubMedGoogle Scholar
• Huang J, Fu X, Chen X, et al. Promising therapeutic targets for treatment of rheumatoid arthritis. Front Immunol. 2021;12:686155.
   PubMed Web of Science ®Google Scholar
• Moelants E, Mortier A, Van Damme J, et al. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol. 2013;91(6):393–401.
   PubMed Web of Science ®Google Scholar
• Lai B, Wu CH, Lai JH. Activation of c-Jun N-terminal kinase, a potential therapeutic target in autoimmune arthritis. Cells. 2020;9(11):2466.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu J, Wang C, et al. Toll-like receptors gene polymorphisms in autoimmune disease. Front Immunol. 2021;12:672346.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.
   PubMed Web of Science ®Google Scholar
• Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther. 2009;11(3):224.
   PubMed Web of Science ®Google Scholar
• Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12:680043.
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191(2):313–320.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev. 2021;20(9):102884.
   PubMed Web of Science ®Google Scholar
• Sims NA. Influences of the IL-6 cytokine family on bone structure and function. Cytokine. 2021;146:155655.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.
   PubMed Web of Science ®Google Scholar
• Li J, Tang R, Shi Z, et al. Nuclear factor-κB in rheumatoid arthritis. Int J Rheum Dis. 2020;23(12):1627–1635.
   PubMed Web of Science ®Google Scholar
• Abdollahi-Roodsaz S, Joosten L, Koenders M, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest. 2008;118(1):205–216.
   PubMed Web of Science ®Google Scholar
• Li X, Xu T, Wang Y, et al. Toll-like receptor-4 signaling: a new potential therapeutic pathway for rheumatoid arthritis. Rheumatol Int. 2014;34(11):1613–1614.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin H, Zhao M, et al. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47(2):136–147.
   PubMed Web of Science ®Google Scholar
• Lorenz W, Buhrmann C, Mobasheri A, et al. Bacterial lipopolysaccharides form procollagen-endotoxin complexes that trigger cartilage inflammation and degeneration: implications for the development of rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R111.
   PubMed Web of Science ®Google Scholar
• Pierer M, Wagner U, Rossol M, et al. Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS One. 2011;6(8):e23539.
   PubMed Web of Science ®Google Scholar
• Popa C, Abdollahi-Roodsaz S, Joosten L, et al. Bartonella quintana lipopolysaccharide is a natural antagonist of toll-like receptor 4. Infect Immun. 2007;75(10):4831–4837.
   PubMed Web of Science ®Google Scholar
• van Loo G, Beyaert R. Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther. 2011;13(3):221.
   PubMed Web of Science ®Google Scholar
• Roman-Blas J, Jimenez S. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14(9):839–848.
   PubMed Web of Science ®Google Scholar
• Liu S, Ma H, Zhang H, et al. Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin Immunol. 2021;230:108793.
   PubMed Web of Science ®Google Scholar